Finance, mergers and appointments
Vertex to acquire Crinetics Pharmaceuticals for US $10 billion
Vertex Pharmaceuticals and Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development and commercialisation of novel therapeutics for...
Cumberland Pharmaceuticals closes strategic transaction with Apotex
Cumberland Pharmaceuticals has made an agreement with a subsidiary of Apotex Health, a Canadian-based pharmaceutical company, to integrate their...
Sanyou Bio and Baiyunshan Xihe join forces to advance innovative radiopharmaceuticals and radiodiagnostics
Sanyou Biopharmaceutical and Guangzhou Baiyunshan Xihe have signed a strategic cooperation agreement.
The partnership will focus on the co-development of...
Codis to acquire Catalent’s Nottingham (UK) facility to create Europe’s leading end-to-end spray dry capability
Codis, a global contract development and manufacturing organisation (CDMO) specialising in spray drying, amorphous solid dispersions and advanced particle...
Vector Science & Therapeutics announces cGMP manufacturing agreement with LyoGenesis Plus for its proprietary peptide portfolio
Vector Science & Therapeutics Chas entered an exclusive licensing and manufacturing agreement with LyoGenesis Plus, a cGMP lyophilisation and...
Helix announces long-term agreement with AstraZeneca to support genomic research for drug discovery and development
Helix, a leading enterprise genomics company, has announced a multi-year relationship with AstraZeneca, a global biopharmaceutical company. Under this...
Evonik invests US$100 million to upgrade its US drug substance contract manufacturing site
Evonik is making a significant investment to strengthen manufacturing capabilities at its Lafayette (Tippecanoe), Indiana facility.
Over the next five...
Myricx Bio to be acquired by Novartis to advance next-generation ADC payloads for oncology with novel NMTi platform
Myricx Bio, a UK-headquartered biotech company focusing on the discovery and development of a novel class of payloads for antibody-drug...
GSK announces commencement of tender offer to acquire Nuvalent
GSK has entered an agreement to acquire Nuvalent, a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology...
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Eli Lilly and Company has successful completed acquisition of Centessa Pharmaceuticals plc.
Centessa is a clinical-stage company developing orexin receptor...
Eli Lilly to acquire both LimmaTech Biologics and Vaccine company in deals totalling US$2.33billion
Eli Lilly is to acquire LimmaTech Biologics and Vaccine Company. Along with its acquisition of Curevo, the companies will...
Eli Lilly and Ascidian enter global research collaboration to develop RNA exon editors for devastating kidney diseases
Ascidian Therapeutics, a bitechnology company seeking to treat human diseases by rewriting RNA, has announced a global research collaboration...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
Popular
Recent Posts
Quantifying Molecular Interactions: a drug developers guide to isothermal titration calorimetry
Since the characterization of binding events is central to understanding any physiological process at the molecular level, biochemical and...
Vertex gains US FDA approval for expanded use of Casgevy in children from two years old with sickle cell disease or transfusion-dependent beta thalassemia
The US Food and Drug Administration (FDA) has approved expanded use of Casgevy (exagamglogene autotemcel) for the treatment of people ages two...
Vertex to acquire Crinetics Pharmaceuticals for US $10 billion
Vertex Pharmaceuticals and Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development and commercialisation of novel therapeutics for...
Cumberland Pharmaceuticals closes strategic transaction with Apotex
Cumberland Pharmaceuticals has made an agreement with a subsidiary of Apotex Health, a Canadian-based pharmaceutical company, to integrate their...
Sanyou Bio and Baiyunshan Xihe join forces to advance innovative radiopharmaceuticals and radiodiagnostics
Sanyou Biopharmaceutical and Guangzhou Baiyunshan Xihe have signed a strategic cooperation agreement.
The partnership will focus on the co-development of...
Codis to acquire Catalent’s Nottingham (UK) facility to create Europe’s leading end-to-end spray dry capability
Codis, a global contract development and manufacturing organisation (CDMO) specialising in spray drying, amorphous solid dispersions and advanced particle...
Vector Science & Therapeutics announces cGMP manufacturing agreement with LyoGenesis Plus for its proprietary peptide portfolio
Vector Science & Therapeutics Chas entered an exclusive licensing and manufacturing agreement with LyoGenesis Plus, a cGMP lyophilisation and...
Helix announces long-term agreement with AstraZeneca to support genomic research for drug discovery and development
Helix, a leading enterprise genomics company, has announced a multi-year relationship with AstraZeneca, a global biopharmaceutical company. Under this...
Keenova announces positive phase 3 results in clinical trial of Xiaflex (collagenase clostridium histolyticum) for treating plantar fibromatosis
Keenova Therapeutics has announced positive results from its phase 3 clinical trial of Xiaflex (collagenase clostridium histolyticum) for the treatment...
Mighty Therapeutics announces first patient dosed in phase 4 confirmatory study of Elamipretide in Barth Syndrome
Mighty Therapeutics, a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare...
Octapharma USA announces expanded FDA approval of Wilate for von Willebrand disease prophylaxis in children under six years
The US Food and Drug Administration (FDA) has approved the use of Wilate (von Willebrand Factor/Coagulation Factor VIII Complex )...
Northwest Biotherapeutics presents updated survival data from phase 3 trial of DCVax-L for Glioblastoma using individual patient level data in multiple independent analyses
Northwest Biotherapeutics, a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, has presented updated survival data from...
Popular
© 2026 Pharma Press Publishing.